CRISPR-Cas9 LGMN Gene Editing Suppresses Breast Cancer Metas

2026-04-12

CRISPR-Cas9 LGMN Gene Editing Suppresses Breast Cancer Metastasis

Study Background and Research Question

Legumain (also known as asparagine endopeptidase, AEP), a lysosomal cysteine protease encoded by the LGMN gene, has been implicated in the invasive and migratory capabilities of various cancer types, including breast, prostate, and gastric cancers. High legumain expression correlates with poor prognosis and increased metastatic potential in solid tumors. Targeting such proteases through precise gene editing could represent a transformative approach in cancer therapy, especially given the challenges posed by metastasis in breast cancer management. The central research question addressed by Wang et al. (2024) is whether co-delivery of Cas9 mRNA and guide RNAs (gRNAs), designed to disrupt LGMN, can efficiently suppress metastatic phenotypes in breast cancer models, both in vitro and in vivo [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6].

Key Innovation from the Reference Study

This study pioneers the simultaneous co-delivery of in vitro-transcribed (IVT) Cas9 mRNA and gRNAs targeting the LGMN gene via lipid nanoparticles (LNPs) to achieve efficient gene disruption in breast cancer cells. A notable methodological innovation is the parallel evaluation of two distinct gRNA template strategies—linearized plasmid (pUC57-T7-gRNA) and synthetic oligonucleotide-based T7-gRNA templates—for IVT using T7 RNA polymerase. These approaches enable direct synthesis of functional gRNAs in vitro, streamlining the production of CRISPR components for gene editing applications [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6].

Methods and Experimental Design Insights

The researchers first engineered two types of gRNA templates: one using linearized pUC57-T7-gRNA plasmid and another employing annealed synthetic oligonucleotides with T7 promoter sequences. Both templates were transcribed in vitro using T7 RNA polymerase to generate gRNAs. For Cas9 mRNA, the authors modified a plasmid backbone to optimize yields during IVT. The resulting IVT RNAs were formulated with lipid nanoparticles for co-delivery into breast cancer cells. Gene editing efficiency was assessed at multiple time points post-transfection (36 h, 48 h, 84 h) by PCR amplification of the LGMN target site and densitometric analysis of editing bands. In vitro phenotypic assays included measurements of lysosomal/autophagic degradation, colony formation, migration, and invasion. In vivo, the metastatic potential of edited cells was evaluated using an experimental lung metastasis model [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6].

Protocol Parameters

assay: IVT transcription yield (gRNA) | value_with_unit: up to 50 μg per 20 μL reaction | applicability: in vitro transcription of gRNA for CRISPR-Cas9 | rationale: Sufficient gRNA is essential for efficient gene editing and downstream functional studies | source_type: product_spec [source_link: https://www.apexbt.com/hyperscribetm-t7-high-yield-rna-synthesis-kit.html]
assay: Cas9 mRNA IVT template input | value_with_unit: 1 μg template per reaction | applicability: synthesis of Cas9 mRNA for LNP formulation | rationale: Adequate input ensures high-yield Cas9 mRNA for co-delivery | source_type: workflow_recommendation
assay: LNP co-formulation | value_with_unit: molar ratio optimized per RNA payload | applicability: co-delivery of Cas9 mRNA and gRNA | rationale: Balanced encapsulation improves editing efficiency and cellular uptake | source_type: workflow_recommendation
assay: PCR-based editing assessment | value_with_unit: triplicate measurements at 36, 48, 84 h | applicability: quantifying editing kinetics | rationale: Time-course analysis validates editing stability and efficiency | source_type: paper [source_link: https://doi.org/10.1038/s41598-024-58765-6]

Core Findings and Why They Matter

The co-delivery of IVT-derived Cas9 mRNA and gRNAs targeting LGMN resulted in effective gene disruption, as evidenced by substantial reductions in LGMN expression and gene-editing ratios measurable by PCR and densitometry. Both plasmid and oligo-derived gRNA templates supported functional gRNA synthesis, though the study highlights nuanced differences in editing efficiency over time [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6]. Functionally, edited breast cancer cells exhibited impaired lysosomal/autophagic degradation, reduced clonogenicity, and diminished migratory and invasive capabilities in vitro. Most significantly, the in vivo lung metastasis model demonstrated that LGMN editing via co-delivered Cas9 mRNA/gRNA led to a marked decrease in metastatic burden. These results underline the utility of IVT-based CRISPR reagent preparation for rapid, scalable, and potentially customizable gene editing in cancer models. The approach is applicable to broader RNA-based genome editing strategies, including RNA vaccine research and RNA interference experiments, where precise and high-yield RNA production is crucial [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6].

Comparison with Existing Internal Articles

Several internal resources discuss high-yield RNA synthesis for advanced research applications. For example, "HyperScribe™ T7 High Yield RNA Synthesis Kit: Precision In..." [link] details how robust IVT platforms support workflows like RNA vaccine development and RNA interference, mirroring the technical needs addressed in the reference study. "Unleashing HyperScribe™ T7 Kit: High-Yield RNA Synthesis ..." [link] specifically discusses the synthesis of capped and biotinylated RNAs for translational applications, including metastatic cancer modeling—closely aligning with the CRISPR-LNP workflow in the reference paper. Together, these articles reinforce the importance of flexible, high-output RNA synthesis kits for enabling rapid prototyping and execution of genome-editing protocols in oncology.

Limitations and Transferability

While the study establishes proof-of-concept for LGMN-targeted CRISPR editing in breast cancer, several limitations are noted. First, the long-term stability and safety of LNP-delivered Cas9 mRNA/gRNA in vivo require further exploration before potential clinical translation. Second, the efficiency and editing kinetics of different gRNA templates, while comparable, may vary depending on sequence context and delivery conditions. Resistance mechanisms—such as mutations in the target site or NHEJ-mediated indels—remain challenges for durable therapeutic efficacy. Additionally, while the approach is technically transferable to other solid tumors where LGMN is implicated, it may not generalize to malignancies lacking upregulated legumain expression [source_type: paper][source_link: https://doi.org/10.1038/s41598-024-58765-6].

Why this cross-domain matters, maturity, and limitations

The reference paper supports direct application of these IVT CRISPR workflows to other cancer models characterized by elevated legumain, but does not extend to unrelated domains (e.g., cardiovascular or antiviral research) within the same evidence base. Broader applications for IVT RNA—such as in RNA interference or vaccine development—are discussed in internal articles but require independent validation for each domain [source_type: workflow_recommendation].

Research Support Resources

For researchers implementing similar protocols, the HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047) from APExBIO provides all necessary reagents for efficient in vitro transcription of gRNAs or Cas9 mRNA using T7 RNA polymerase. The kit supports synthesis of capped, dye-labeled, or biotinylated RNA, enabling workflows for capped RNA synthesis, RNA interference, or probe generation in gene-editing studies [source_type: product_spec][source_link: https://www.apexbt.com/hyperscribetm-t7-high-yield-rna-synthesis-kit.html]. This resource can streamline reproducible, high-yield RNA production for both mechanistic and translational research in line with the reference study's methodologies.